Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: Montelukast: 10 mg Montelukast tablet daily at bed time for 10 days
Control Intervention1: Placebo: Similar looking palcebo tablet at bed time for 10 days.
Sponsors
NIL
Eligibility
Inclusion criteria
Inclusion criteria: All patients above the age of 14 years both males and females, admitted with a diagnosis of mild or moderate COVID -19 (on the basis of a positive RT-PCR report) at our facility during the study period (01/09/2020-31/12/2020)
Exclusion criteria
Exclusion criteria: 1. Patients with a known allergy to or adverse drug reaction with Montelukast. 2. Patients unable to provide consent or unwilling to participate in the study. 3. Patients included in any other ongoing trial will be excluded from the study. 4. Patients below the age of 14 years will be excluded from the study. 5. Pregnant and Lactating Females will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Progression of the disease to severe grade. 2. Admission to ICU . 3. Need for mechanical ventilation. 4. In-hospital mortalityTimepoint: At every week | — |
Secondary
| Measure | Time frame |
|---|---|
| when Patient becomes asymptomatic .Timepoint: At 2 to 4 weeks | — |
Countries
India
Contacts
Public ContactDR VIJAY KUMAR
AIIMS PATNA
Outcome results
None listed